- The role of the novel D2/beta2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a large-scale clinical investigationL C Laursen
Department of Lung Medicine, KAS Gentofte, Hellerup, Denmark
Respir Med 97:S23-33. 2003..These studies, utilizing the novel BCSS, have clearly illustrated that, despite initial symptomatic improvement with sibenadet therapy, this clinical benefit was not sustained over the course of the study...
- Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within three days in mild asthma: time course after onset and cessation of treatmentA R A Sovijarvi
Department of Clinical Physiology, Helsinki University Central Hospital, Helsinki, Finland
Thorax 58:500-4. 2003..The effect of inhaled fluticasone propionate (FP) on BHR in patients with mild persistent asthma was assessed using time intervals of hours, days and weeks...
- Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthmaP Kuna
Division of Pneumonology and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland
Respir Med 100:2151-9. 2006..Budesonide/formoterol administered once daily in the evening is a convenient treatment regimen that is as effective in improving asthma control as twice-daily dosing in patients with mild to moderate persistent asthma...
- Airway inflammation and basement membrane tenascin in newly diagnosed atopic and nonatopic asthmaE M Karjalainen
Clinical Research Unit of Pulmonary Medicine, Department of Medicine, Helsinki University Central Hospital, Finland
Respir Med 97:1045-51. 2003..These findings suggest that inflammatory cells may have a regulatory role in tenascin expression in atopic asthma...